ORIGINAL CONTRIBUTION
|
|
- Myles Watts
- 5 years ago
- Views:
Transcription
1 ORIGINAL CONTRIBUTION Plasma Levels of -Amyloid (1-4), -Amyloid (1-42), and Total -Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins Kina Höglund, MSc; Olov Wiklund, MD, PhD; Hugo Vanderstichele, PhD; Oliver Eikenberg, PhD; Eugeen Vanmechelen, PhD; Kaj Blennow, MD, PhD Background: Epidemiological studies suggest that statins reduce the risk of developing Alzheimer disease. Cell and animal experiments have revealed a connection between cholesterol metabolism and the processing of amyloid precursor protein. To our knowledge, the mechanism for statins in risk reduction of Alzheimer disease is unknown. Objective: To test the effect of statin treatment on -amyloid (A ) metabolism in humans. Design: A prospective, randomized, dose-finding 36- week treatment trial with statins. Plasma samples were taken at baseline (week ) and at weeks 6, 12, and 36. Setting: Outpatient clinical study at a university hospital. Patients: Thirty-nine patients who met the criteria for hypercholesterolemia. Interventions: Patients were randomized to oral treatment with either simvastatin or atorvastatin calcium according to the following regimen: simvastatin, 4 mg/d, or atorvastatin, 2 mg/d, for 6 weeks; followed by simvastatin, 8 mg/d, or atorvastatin, 4 mg/d, for 6 weeks; and finally, simvastatin, 8 mg/d, or atorvastatin, 8 mg/d, for 24 weeks. Main Outcome Measures: Plasma levels of A (1-4) and A (1-42) were measured using 2 enzyme-linked immunosorbent assays, and total A was quantified by Western blotting. Results: Treatment with both statins reduced total plasma cholesterol levels by 56% (P=.). The plasma levels of A (1-4), A (1-42), and total A were stable in individual patients during the treatment period. No significant change in the level of A (1-4), A (1-42), or total A was found. Conclusion: This study questions the effect of statins on the processing of amyloid precursor protein in humans. Arch Neurol. 24;61: From the Institute of Clinical Neuroscience (Ms Höglund and Dr Blennow) and the Wallenberg Laboratory (Dr Wiklund), The Sahlgrenska Academy at Göteborg University, Göteborg, Sweden; INNOGENETICS NV, Zwijnaarde, Belgium (Drs Vanderstichele and Vanmechelen); and ABETA GmbH, Heidelberg, Germany (Dr Eikenberg). PREVIOUS STUDIES SUPPORT THE theory that the formation and aggregation of -amyloid (A ), the major constituent of senile plaques in brain and blood vessels, is critical for the initiation of Alzheimer disease (AD). The A peptide is produced in 2 major forms, A 4 and A 42, during the processing of the integral plasma membrane protein, amyloid precursor protein (APP). Secreted soluble A is a product of normal cell metabolism, 1 and is found in various body fluids, including cerebrospinal fluid (CSF) and plasma. 2,3 Several studies have suggested an association between AD, A, and cholesterol metabolism. Clinical studies have revealed that patients with AD have elevated levels of cholesterol in the plasma 4 and that the plasma level of apolipoprotein E, 5 the main lipid transporter protein in the brain, 6 is related to AD. Longitudinal studies 7,8 have suggested that an elevated midlife level of cholesterol is a risk factor for AD, and recent retrospective clinical studies 9-11 have indicated that patients treated with statins have a reduced prevalence of AD. Statins reduce de novo cholesterol synthesis by inhibiting the rate-limiting enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase, which leads to a decrease in low-density lipoprotein cholesterol level in human plasma. In vitro studies 12,13 have shown that cholesterol modulates the processing of APP. The hypothesis that lowering cholesterol levels favors the nonamyloidogenic pathway has further been supported by animal studies. 12,14 However, there are also 2 prospective studies 15,16 that do not support the connection between statin treatment and reduced prevalence of AD. 333
2 Levels of Total Cholesterol, A (1-4), and A (1-42) at Baseline and After 6, 12, and 36 Weeks of Treatment With Simvastatin or Atorvastatin Calcium* Treatment Total Cholesterol, mg/dl It is believed that cholesterol in the brain mainly results from de novo synthesis of cholesterol in the cells. 17 The efflux of cholesterol is in the form of 24Shydroxycholesterol. 18 Two recent studies 18,19 have demonstrated that patients with early-onset AD and vascular dementia have elevated concentrations of 24Shydroxycholesterol in their plasma, indicating an overproduction of cholesterol in the brain. Support for this hypothesis has been given in 2 studies 2,21 showing that cholesterol metabolism in the human brain was affected by treatment with statins and effects were seen after 6 weeks of treatment. To test the effect of statins on A metabolism in humans, we examined the plasma levels of A (1-4), A (1-42), and total A in longitudinal samples from patients with hypercholesterolemia who were treated with statins. We observed that pharmacologically attainable concentrations of atorvastatin calcium or simvastatin did not affect the plasma levels of A (1-4),A (1-42),or total A. METHODS A (1-4), pg/ml A (1-42), pg/ml Atorvastatin (n = 2) Baseline 263 (244-35) 141 ( ) 23 (21-31) 6 wk, 2 mg/d 17 ( ) 138 ( ) 25 (21-28) 12 wk, 4 mg/d 151 (143-17) 147 ( ) 25 (22-28) 36 wk, 8 mg/d 143 ( ) 143 ( ) 25 (23-28) Simvastatin (n = 19) Baseline 325 (244-35) 148 ( ) 35 (21-46) 6 wk, 4 mg/d 21 ( ) 153 ( ) 34 (23-48) 12 wk, 8 mg/d 186 (174-25) 163 ( ) 36 (27-48) 36 wk, 8 mg/d 186 (135-25) 157 ( ) 3 (24-44) Abbreviation: A, -amyloid. SI conversion factor: To convert total cholesterol to millimoles per liter, multiply by.259. *Data are given as median (interquartile range). The interquartile range is from the 25th percentile to the 75th percentile. This study is an extension of a substudy of a larger multicenter investigation. 22 In the present study, 39 subjects (27 men and 12 women) were included, and all had completed the entire treatment; 19 patients were treated with simvastatin, and 2 with atorvastatin. The mean age of the 39 subjects was 55 years (range, years). Eight patients were excluded from the multicenter investigation because no samples were available. Inclusion criteria were the same as for the main study, 23 published separately. To qualify, all patients were required to have a low-density lipoprotein cholesterol level of mg/dl or more ( 4.19 mmol/l) and a triglycerides level of mg/dl or less ( 3.97 mmol/l). At baseline, the mean (SD) plasma level of total cholesterol was 31.5 (54.2) mg/dl (7.8 [1.4] mmol/l). The medical history of all patients was studied, and all patients underwent a thorough clinical examination to exclude cognitive impairment. Following the start of a 4-week run-in period, the patients were randomized to 1 of 2 treatments: simvastatin, 4 mg/d, or atorvastatin, 2 mg/d, for 6 weeks; followed by simvastatin, 8 mg/d, or atorvastatin, 4 mg/d, for 6 weeks; and finally, simvastatin, 8 mg/d, or atorvastatin, 8 mg/d, for 24 weeks. Other ongoing lipid-lowering treatment was discontinued at least 8 weeks before randomization. The EDTA-plasma samples were collected at baseline (week ) and at the end of each treatment period (weeks 6, 12, and 36), and then frozen. All samples analyzed by an enzyme-linked immunosorbent assay (ELISA) were analyzed on the same day. The study was approved by the local ethics committees, and patients were included after giving informed consent. The study was performed according to the Declaration of Helsinki. BIOCHEMICAL ANALYSIS The plasma A (1-42) concentration was determined using the highsensitivity format of one assay (INNOTEST -AMYLOID (1-42) ; INNOGENETICS NV) with a detection limit of 7.8 pg/ml. The assay and its characteristics have previously been described in detail. 24 The method is based on the antibody 21F12, specific for the carboxyl terminus of A 42 ; and the biotinylated detection antibody 3D6, specific for the amino terminus, including amino acid D1 of A (1-42). The concentration of A 4 plasma levels was determined by a research prototype version of another assay (INNOTEST -AMYLOID (1-4) ; INNOGENETICS NV) with a detection limit of 7.8 pg/ml. The method is based on the antibody R293, specific to the carboxyl terminus of A (1-4) ; and the biotinylated detection antibody 3D6. The total levels of A were measured using an advanced version of the sensitive Western blot assay according to an internally developed protocol (ABETA GmbH). The method is based on the monoclonal antibody W-2 (ABETA GmbH), which recognizes the 4-1 residue of A. Quantification was performed using computer software (Quantity One; BioRad Laboratories, Hercules, Calif). The synthetic peptide from the assay used (INNOTEST -AMYLOID (1-42) ) was used as a standard. A control sample was loaded onto all gels, and was quantified and used subsequently as an internal quality control. Wiklund et al 22 provide further information on the characterization of lipids and lipoproteins. STATISTICAL ANALYSIS All statistical procedures were performed using a commercially available software program (SPSS for Windows; SPSS Inc, Chicago, Ill). The Pearson product moment correlation coefficient was used for correlations. Comparison between groups was performed using the nonparametric Kruskal-Wallis test. We used the Wilcoxon matched-pair signed rank test to compare differences at baseline and after 6, 12, or 36 weeks of treatment. P.5 was considered significant. RESULTS LIPIDS Treatment with either atorvastatin or simvastatin for 36 weeks produced, as expected, significant effects on total cholesterol levels (even after just 6 weeks of treatment). For the combined groups, total cholesterol levels were reduced by 56% (P=.) after 36 weeks of treatment. In the group treated with atorvastatin, the reduction was 53% and in the simvastatin group, 57% (P=. for both). Changes in total cholesterol levels are given in the Table. The major adverse effect was gastrointestinal symptoms; however, no patient in either treatment group experienced myopathy. 334
3 A (1-4) AND A (1-42) Neither simvastatin nor atorvastatin administration significantly affected the plasma levels of A (1-4) (P=.99) or A (1-42) (P=.1). At baseline, the mean (SD) plasma level of A (1-4) for the combined groups (N=39) was 148 (44) pg/ml; after 36 weeks of treatment, it was 152±36 pg/ml. Mean (SD) levels of A (1-42) for the combined groups (N=39) were as follows: 33 (23) pg/ml at baseline and 32 (22) pg/ml after 36 weeks of treatment. Values of A (1-4) and A (1-42) in plasma at baseline and after 6, 12, and 36 weeks of treatment are given in the Table. Figure 1 depicts the levels of A (1-4) and A (1-42) for the combined groups at baseline and after 6, 12, and 36 weeks of treatment. There were broad variations between individuals, but the levels were stable between samples taken at baseline and after 6, 12, or 36 weeks of treatment in individual subjects. Individual plasma levels of cholesterol and A (1-42) before and during treatment are illustrated in Figure 2. The levels of A (1-42) and A (1-4) corresponded, ie, patients with higher levels of A (1-42) also had higher levels of A (1-4), as recognized by the correlation coefficients (r week =.42 [P.1], r week 6 =.4 [P.1], r week 12 =.45 [P.4], and r week 36 =.35 [P.1]). TOTAL A Because of the limited sample volume (due to an earlier analysis), selected samples only (n=14) were analyzed by Western blotting. Neither simvastatin nor atorvastatin treatment significantly changed the levels of total A (P=.59). For the combined treatment groups (n=14), the mean±sd baseline level of A was 228 (15) pg/ml; after 36 weeks of treatment, it was 219 (172) pg/ml. Broad variations between individuals were seen, but the levels were relatively stable between samples taken at baseline and after 6, 12, or 36 weeks of treatment in individual subjects. COMMENT Aβ Level, pg/ml Aβ(1-42) Aβ (1-4) Figure 1. Histogram illustrating the levels of 2 -amyloids (A s), A (1-4) and A (1-42), in plasma, measured by an enzyme-linked immunosorbent assay, at baseline and after 6, 12, and 36 weeks of treatment with atorvastatin calcium or simvastatin. Data are given as mean (SD) levels for the combined groups (N=39). At several time points after treatment with 2 different statins, simvastatin or atorvastatin, no significant change in the levels of either A (1-4) or A (1-42) was observed compared with baseline levels. The levels of A (1-4) and A (1-42) measured at baseline and after 6, 12, or 36 weeks of treatment were remarkably stable within each patient, and there was no significant difference between the 2 treatment groups. There was no control group in this study. However, the CSF levels of A 42 have been shown to be stable in untreated patients with AD. 25 Although ELISA is sensitive, one potential drawback when measuring A is that the measurement can be affected if other proteins bind to A and mask the epitope of antibodies used in the assay. Therefore, selected plasma samples were also quantified using an advanced sensitive Western blot; where possible, protein complexes were separated by subjecting the samples to sodium dodecyl sulfate and heat treatment. The results corresponded well with the ELISA measurements, and no significant change in plasma A level was seen during treatment with statins. Thus, it is unlikely that the lack of effect on plasma A (1-4) and A (1-42) measured by the present ELISA (INNOGENETICS NV) is due to methodological shortcomings. To our knowledge, this is the first longitudinal treatment study of patients with hypercholesterolemia in which the plasma levels of A have been studied. In a case-control study, 29 the CSF level of A in patients with hypercholesterolemia, treated with statins or untreated, was compared with that of healthy controls. In agreement with our findings, no effect on A metabolism was seen. It was demonstrated earlier 3 that levels of A (1-42) in the CSF and plasma were unchanged in patients with AD treated with simvastatin for 12 weeks. However, the levels of sapp ( -cleaved soluble APP) and sapp ( -cleaved soluble APP) were significantly reduced, which could indicate that altered APP processing is not reflected in plasma or CSF A levels. In a placebo-controlled double-blind study, 31 patients with AD were treated with simvastatin for 26 weeks. In the total AD group, simvastatin did not significantly alter CSF levels of A (1-4) or A (1-42), in agreement with our results. However, a post hoc analysis revealed that the levels of A (1-4) were slightly ( 5.7%±6.5%), but significantly (n=8; P.5), reduced in patients with mild AD. In the present study, the plasma level of A was measured. Buxbaum and colleagues 32 recently published a study on serum levels of A in patients with hypercholesterolemia who were treated for 3 months with controlreleased lovastatin. They observed a concentrationdependent decrease in A using a different ELISA, based on different antibodies: 4G8, specific to amino acids 17 to 24 of the A peptide; and 6E1, specific to amino acids5to1ofthea peptide. The serum level of A has 335
4 A B Total Cholesterol Level, mg/dl Aβ (1-42) Level, pg/ml C D Total Cholesterol Level, mg/dl Aβ (1-42) Level, pg/ml Figure 2. The reduction of total cholesterol levels in plasma is shown after treatment with atorvastatin calcium (n=2) (A) or simvastatin (n=19) (C). The reduction can already be seen after 6 weeks of treatment. To convert total cholesterol to millimoles per liter, multiply by.259. The stability of -amyloid (1-42) (A (1-42) ) levels in the plasma is also shown, measured by an enzyme-linked immunosorbent assay, after treatment with atorvastatin (n=2) (B) or simvastatin (n=19) (D). been considered to be under the detection limit using our assay (INNOTEST -AMYLOID (1-42) ). 24 In agreement with the results in the present study, there are 2 prospective studies 15,16 that do not support the connection between statin treatment and reduced prevalence of AD. In these 2 studies, no effect on developing dementia was seen after statin treatment. However, in both of these studies, patients with cognitive impairment or dementia were excluded, by excluding either patients with a Mini-Mental State Examination score below or patients with dementia. 16 The dosages of statins given in the clinical studies mentioned were between 2 and 8 mg/d. However, in animal studies 12 and cell culture experiments, 12,13,33 the dosage of statins exceeds these dosages many times over. The differences in dosage between animal/cell culture studies and human studies may explain the lack of effect of pharmacological dosages of statins on A in the present study. Although cell culture and animal studies suggest that statins reduce A production, the present and other clinical studies show no effect or only a minor effect on plasma and CSF levels of A after statin treatment. Because statins also have other nonlipid effects, such as antiinflammatory or neuroprotective effects, 34 the potential protective effect of statins on AD seen in epidemiological studies may not be through the inhibition of cholesterol synthesis. The origin of A in plasma is still unclear. No correlation between CSF and plasma levels of A has been seen, 23,35 nor is there a correlation between CSF, A 42, and blood-brain barrier deficits, which suggests that plasma A 42 is not derived from the brain but is secreted 336
5 peripherally. Despite a marked reduction in cholesterol levels, we did not observe any change in plasma levels of A. It is possible that statins may affect A metabolism in the brain, but not peripherally. However, several studies 28-3 have found no change in CSF levels or only minor effects in mild AD cases after statin treatment. In conclusion, further studies are needed to examine the mechanism by which statins may reduce the risk of developing AD. Accepted for publication October 28, 23. Author contributions: Study concept and design (Ms Höglund and Drs Wiklund and Blennow); acquisition of data (Ms Höglund and Drs Wiklund and Eikenberg); analysis and interpretation of data (Ms Höglund and Drs Vanderstichele, Eikenberg, Vanmechelen, and Blennow); drafting of the manuscript (Ms Höglund and Drs Vanderstichele and Blennow); critical revision of the manuscript for important intellectual content (Ms Höglund and Drs Wiklund, Eikenberg, Vanmechelen, and Blennow); statistical expertise (Dr Blennow); obtained funding (Ms Höglund and Drs Wiklund, Vanmechelen, and Blennow); administrative, technical, and material support (Drs Vanderstichele, Eikenberg, Vanmechelen, and Blennow); study supervision (Drs Wiklund and Blennow). This study was supported by projects 1156, 1213, and 142 of the Swedish Medical Research Council, Stockholm, Sweden; Alzheimerfonden, Lund, Sweden; and Stiftelsen för Gamla Tjänarinnor, Stockholm. We thank Pankaj Mehta, MD, PhD, for the polyclonal antibodies against Aβ 4 ; Tobias Hartmann, PhD, for introducing us to the blotting method for Aβ, and for sharing his scientific knowledge; and Inge Tomic, Mareike Grees, and Monique Beumer for their skillful technical assistance. Corresponding author: Kina Höglund, MSc, Experimental Neuroscience Section, Institute of Clinical Neuroscience, Neurolab, SU/Mölndal, S-4318 Mölndal, Sweden ( kina.hoglund@neuro.gu.se). REFERENCES 1. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer s -peptide from biological fluids. Nature. 1992;359: Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid 42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55: Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid -peptide 1-42 and incipient Alzheimer s disease. Ann Neurol. 1999;46: Giubilei F, D Antona R, Antonini R, et al. Serum lipoprotein pattern variations in dementia and ischemic stroke. Acta Neurol Scand. 199;81: Jarvik GP, Wijsman EM, Kukull WA, et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer s disease: a case-control study. Neurology. 1995;45: Poirier J. Apolipoprotein E and Alzheimer s disease: a role in amyloid catabolism. Ann N Y Acad Sci. 2;924: Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer s disease in later life: longitudinal, population based study. BMJ. 21; 322: Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E 4 allele, and Alzheimer s disease. Neuroepidemiology. 1998;17: Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 22;59: Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet. 2; 356: Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2;57: Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer s disease beta-amyloid peptides A 42 and A 4 in vitro and in vivo. Proc Natl Acad Sci U S A. 21;98: Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of -amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998; 95: Sparks DL, Kuo YM, Roher A, et al. Alterations of Alzheimer s disease in the cholesterol-fed rabbit, including vascular inflammation: preliminary observations. Ann N Y Acad Sci. 2;93: Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 22; 36: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 2,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 22;36: Kabara JJ. A critical review of brain cholesterol metabolism. Prog Brain Res. 1973; 4: Lutjohann D, Breuer O, Ahlborg G, et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A. 1996;93: Papassotiropoulos A, Lutjohann D, Bagli M, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res. 22; 36: Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24Shydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 23;6: Locatelli S, Lutjohann D, Schmidt HH, et al. Reduction of plasma 24Shydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol. 22;59: Wiklund O, Mattsson-Hulten L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med. 22; 251: Illingworth DR, Crouse JR 3rd, Hunninghake DB, et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 21;17: Vanderstichele H, Van Kerschaver E, Hesse C, et al. Standardization of measurement of -amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid. 2;7: Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid -amyloid (1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56: Zlokovic BV. Cerebrovascular transport of Alzheimer s amyloid and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. 1996;59: Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J Alzheimer s A interaction. J Biol Chem. 1995;27: Biere AL, Ostaszewski B, Stimson ER, et al. Amyloid -peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem. 1996;271: Fassbender K, Stroick M, Bertsch T, et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 22;59: Sjogren M, Gustafsson K, Syversen S, et al. Treatment with simvastatin in patients with Alzheimer s disease lowers both - and -cleaved amyloid precursor protein. Dement Geriatr Cogn Disord. 23;16: Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 22;52: Buxbaum JD, Cullen EI, Friedhoff LT. Pharmacological concentrations of the HMG- CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer -amyloid peptide in vitro and in patients. Front Biosci. 22;7:a5-a Frears ER, Stephens DJ, Walters CE, et al. The role of cholesterol in the biosynthesis of -amyloid. Neuroreport. 1999;1: Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348: Mehta PD, Pirttila T, Patrick BA, et al. Amyloid protein 1-4 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett. 21;34:
Platelet Amyloid Precursor Protein Processing: A Biomarker for Alzheimer s Disease.
Platelet Amyloid Precursor Protein Processing: A Biomarker for Alzheimer s Disease. Roger N. Rosenberg, MD Alzheimer s Disease Center University of Texas Southwestern Medical Center at Dallas Disclosures:
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationDuring the last 2 decades, evidence has accumulated that a high cholesterol level may
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD Cholesterol Level and Statin Use in Alzheimer Disease I. Review of Epidemiological and Preclinical Studies Nina E. Shepardson, MS; Ganesh M. Shankar,
More informationAssociation of statin use with risk of dementia: A meta-analysis of prospective cohort studies
bs_bs_banner Geriatr Gerontol Int 2013; 13: 817 824 REVIEW ARTICLE Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies Yu Song, 1 Hongwei Nie, 2 * Yong Xu, 1
More informationThe Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment
Journal of Gerontology: MEDICAL SCIENCES 2002, Vol. 57A, No. 7, M414 M418 Copyright 2002 by The Gerontological Society of America The Impact of the Use of Statins on the Prevalence of Dementia and the
More informationStatins and Cognition A Focus on Mechanisms
Statins and Cognition A Focus on Mechanisms Note: Deleted copyrighted graphs/tables are described In red text and source references are provided Disclosures: SPARCL Steering Committee and past consultant
More informationORIGINAL CONTRIBUTION. Evaluation of CSF-tau and CSF-A 42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
ORIGINAL CONTRIBUTION Evaluation of CSF-tau and CSF-A 42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice Niels Andreasen, MD, PhD; Lennart Minthon, MD, PhD; Pia Davidsson, PhD; Eugeen
More informationORIGINAL CONTRIBUTION. Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
ORIGINAL CONTRIBUTION Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women Kristine Yaffe, MD; Elizabeth Barrett-Connor, MD; Feng Lin, MS; Deborah Grady, MD Background: Few strategies
More informationR aised plasma concentrations of cholesterol have been
1624 PAPER Lipid lowering agents are associated with a slower cognitive decline in Alzheimer s disease I Masse, R Bordet, D Deplanque, A Al Khedr, F Richard, C Libersa, F Pasquier... See Editorial Commentary,
More informationHuman Neurology 3-Plex A
Human Neurology 3-Plex A SUMMARY AND EXPLANATION OF THE TEST The Human N3PA assay is a digital immunoassay for the quantitative determination of total Tau, Aβ42, and Aβ40 in human plasma and CSF. Determination
More informationORIGINAL CONTRIBUTION. Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid -Protein Levels
ORIGINAL CONTRIUTION Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid -Protein Levels Hiroaki Fukumoto, PhD; Marsha Tennis, RN; Joseph J. Locascio, PhD; radley T. Hyman, MD, PhD; John H. Growdon,
More informationORIGINAL CONTRIBUTION. Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
ORIGINAL CONTRIBUTION Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease Preliminary Results D. Larry Sparks, PhD; Marwan N. Sabbagh, MD; Donald J. Connor, PhD, PhD; Jean Lopez, MSN,
More informationCholesterol-Lowering Drugs And Alzheimer S Disease
Future Lipidology ISSN: 1746-0875 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/tlip19 Cholesterol-Lowering Drugs And Alzheimer S Disease Gunter P Eckert, Walter E Müller & Gibson W.
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationCLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD. Statin Use and the Risk of Incident Dementia
CLINICAL TRIALS SECTION EDITOR: IRA SHOULSON, MD Statin Use and the Risk of Incident Dementia The Cardiovascular Health Study Thomas D. Rea, MD, MPH; John C. Breitner, MD; Bruce M. Psaty, MD, PhD; Annette
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationChapter 1. Introduction
The older people get, the bigger the chance of losing cognitive abilities and ultimately to develop dementia. Increasing age is the largest known risk factor of dementia, with a prevalence of 1% in people
More informationTHE ASSOCIATION BETWEEN CHOLESTEROL LEVELS AND BRACHIAL/AORTIC AUGMENTATION INDEX VERSUS COGNITIVE STATUS IN PATIENTS WITH CARDIOVASCULAR RISK FACTORS
Arch. Biol. Sci., Belgrade, 64 (2), 419-426, 2012 DOI:10.2298/ABS1202419J THE ASSOCIATION BETWEEN CHOLESTEROL LEVELS AND BRACHIAL/AORTIC AUGMENTATION INDEX VERSUS COGNITIVE STATUS IN PATIENTS WITH CARDIOVASCULAR
More informationApolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer s disease
94 Review TRENDS in Molecular Medicine Vol.9 No.3 March 2003 Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer s disease Judes Poirier McGill Centre for Studies
More informationORIGINAL CONTRIBUTION. Plasma and Cerebrospinal Fluid Levels of Amyloid Proteins 1-40 and 1-42 in Alzheimer Disease
ORIGINAL CONTRIBUTION Plasma and Cerebrospinal Fluid Levels of Amyloid Proteins 1-40 and 1-42 in Alzheimer Disease Pankaj D. Mehta, PhD; Tuula Pirttilä, MD, PhD; Sangita P. Mehta, MS; Eugene A. Sersen,
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationAssociation of statin use with cognitive decline in elderly African Americans
Association of statin use with cognitive decline in elderly African Americans S.J. Szwast, MD H.C. Hendrie, MB, ChB, DSc K.A. Lane, MS S. Gao, PhD S.E. Taylor, MA F. Unverzagt, PhD J. Murrell, PhD M. Deeg,
More informationCerebrospinal fluid tau protein as a biochemical marker for Alzheimer s disease: a community based follow up study
298 Department of Rehabilitation, Piteå River Valley Hospital, Piteå, Sweden N Andreasen Innogenetics NV, Gent, Belgium E Vanmechelen A Van de Voorde Department of Clinical Neuroscience and Family Medicine,
More informationBiochemical Diagnosis of Alzheimer Disease by Measuring the Cerebrospinal Fluid Ratio of Phosphorylated tau Protein to -Amyloid Peptide 42
ORIGINAL CONTRIBUTION Biochemical Diagnosis of Alzheimer Disease by Measuring the Cerebrospinal Fluid Ratio of Phosphorylated tau Protein to -Amyloid Peptide 42 Alessia Maddalena, MD; Andreas Papassotiropoulos,
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationUse of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study Fn1 C. Cramer, PhD M.N. Haan, DrPH S. Galea, MD, DrPH K.M. Langa, MD, PhD J.D. Kalbfleisch, PhD Address
More informationDiabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian
Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes
More informationORIGINAL CONTRIBUTION. Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults
ORIGINAL CONTRIBUTION Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults Erik Stomrud, MD; Oskar Hansson, MD, PhD; Henrik Zetterberg, MD, PhD; Kaj
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationCholesterol targets and therapy Thomas C. Andrews, MD, FACC
Cholesterol targets and therapy Thomas C. Andrews, MD, FACC 2 Statins in secondary prevention Still first line therapy! First line therapy: high intensity statin Dose individualized based on baseline LDL
More informationORIGINAL INVESTIGATION. Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease
Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease The Framingham Study ORIGINAL INVESTIGATION Zaldy Sy Tan, MD, MPH; Sudha Seshadri, MD; Alexa Beiser, PhD; Peter W. F. Wilson, MD; Douglas
More informationLipid metabolism in Alzheimer s and Parkinson s disease
Future Lipidology ISSN: 1746-0875 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/tlip19 Lipid metabolism in Alzheimer s and Parkinson s disease Qin Xu & Yadong Huang To cite this article:
More informationIn 2001, the National Cholesterol Education Program
At a Glance Practical Implications p 330 Author Information p 333 Full text and PDF www.ajpblive.com Lipid Management When Converting Fluvastatin to Pravastatin: Medication Use Evaluation Original Research
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationAPPENDIX SUPPLEMENTARY METHODS Control group criteria for each center... 2 strem2 ELISA protocol... 3 APPENDIX TABLES... 4
APPENDIX Content APPENDIX SUPPLEMENTARY METHODS... 2 Control group criteria for each center... 2 strem2 ELISA protocol... 3 APPENDIX TABLES... 4 Appendix Table S1. CSF core biomarkers cut-offs for each
More informationOverview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis
Original Article Page 1 of 14 Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis Xi-Chen Zhu, Wen-Zhuo Dai, Tao Ma
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationCritical Review. Cholesterol and Alzheimer s Disease: A Still Poorly Understood Correlation
IUBMB Life, 64(12): 931 935, December 2012 Critical Review Cholesterol and Alzheimer s Disease: A Still Poorly Understood Correlation Roberta Ricciarelli 1 *, Elisa Canepa 1, Barbara Marengo 1, Umberto
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationStatins and stroke prevention
Acta neurol. belg., 2003, 103, 13-18 Statins and stroke prevention P. LALOUX Service de Neurologie, Cliniques Universitaires de Mont-Godinne, Université Catholique de Louvain, Yvoir, Belgium Key words
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationThe All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.
ENCLOSURE 5 APPENDIX 1 Paper presented to AWMSG in June 2006 AWPAG considered comments recorded in AWMSG minutes in July 2006 Paper subsequently updated and brought back to AWMSG for endorsement This paper
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationApolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer s disease and cardiovascular disease
FEATURE REVIEW (2006) 11, 721 736 & 2006 Nature Publishing Group All rights reserved 1359-4184/06 $30.00 www.nature.com/mp Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk
More informationAtorvastatin route of administration
Atorvastatin route of administration 8-3-2017 Atorvastatin Calcium. Atorvastatin Calcium Combinations; Routes.. Petrella G et al. Effects of simvastatin and atorvastatin administration on. 1-3-2017 Atorvastatin
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationThe Primary Care Guide To Understanding The Role Of The Metabolic Syndrome In Cognitive Decline Of Older Persons
The Primary Care Guide To Understanding The Role Of The Metabolic Syndrome In Cognitive Decline Of Older Persons 1. Defining the Metabolic Syndrome A Primary care practice often includes numerous patients
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationThe Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study
The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study Masayasu Matsumoto 1, Naohisa Hosomi 1, Yoji Nagai 2, Tatsuo Kohriyama 3, Shiro
More informationLipid metabolism in cognitive decline and dementia
BRESR-100389; No. of pages: 18; 4C: BRAIN RESEARCH REVIEWS XX (2005) XXX XXX available at www.sciencedirect.com www.elsevier.com/locate/brainresrev Review Lipid metabolism in cognitive decline and dementia
More informationStatins and control of MHC2TA gene transcription
Statins and CIITA 4 4 Statins and control of MHC2TA gene transcription 4 Hedwich F. Kuipers and Peter J. van den Elsen Nature Medicine, 2005, 11: 365-366 Statins and control of MHC2TA gene transcription
More informationORIGINAL CONTRIBUTION. Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
ORIGINAL CONTRIBUTION Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease Miia Kivipelto, MD, PhD; Tiia Ngandu, BM; Laura Fratiglioni, MD, PhD; Matti Viitanen, MD,
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationAlzheimer s disease: the cholesterol connection
Alzheimer s disease: the cholesterol connection Luigi Puglielli 1,2, Rudolph E. Tanzi 2 and Dora M. Kovacs 1,2 1 Neurobiology of Disease Laboratory and 2 Genetics and Aging Research Unit, CAGN, Massachusetts
More informationORIGINAL INVESTIGATION. Body Mass Index, Other Cardiovascular Risk Factors, and Hospitalization for Dementia
ORIGINAL INVESTIGATION Body Mass Index, Other Cardiovascular Risk Factors, and Hospitalization for Dementia Annika Rosengren, MD, PhD; Ingmar Skoog, MD, PhD; Deborah Gustafson, PhD; Lars Wilhelmsen, MD,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationDECREASED SERUM LIPIDS IN PATIENTS WITH PROBABLE ALZHEIMER'S DISEASE
& DECREASED SERUM LIPIDS IN PATIENTS WITH PROBABLE ALZHEIMER'S DISEASE Orhan Lepara¹*, Amina Valjevac¹, Azra Alajbegović², Asija Zaćiragić¹, Emina Nakaš-Ićindić¹ ¹ Institute of Physiology and Biochemistry,
More informationDelirium, Apo-E status, and AD CSF biomarkers
Delirium, Apo-E status, and AD CSF biomarkers Zhongcong Xie, M.D., Ph.D. Geriatric Anesthesia Research Unit Department of Anesthesia, Critical Care and Pain Medicine Massachusetts General Hospital Harvard
More informationChanges in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer s disease
Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer s disease Maura Heverin,* Nenad Bogdanovic, Dieter Lütjohann, Thomas Bayer,** Irina Pikuleva, Lionel
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Cost-effectiveness analysis of combination statin/ezetimibe therapy for the treatment of elevated low-density lipoprotein cholesterol Gryskiewicz K A, Coleman C I, Gillespie E L, White C M Record Status
More informationThe cost-effectiveness of a new statin (rosuvastatin) in the UK NHS Palmer S J, Brady A J, Ratcliffe A E
The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS Palmer S J, Brady A J, Ratcliffe A E Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationHOMOTAURINE INVESTIGATIONAL SUMMARY
HOMOTAURINE INVESTIGATIONAL SUMMARY Amyloid Precursor Protein (brain) Amyloid Aß Amyloid fibril Amyloid plaque action mechanism Aisen PS. Presented at: 9th International Geneva Springfield Symposium on
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationSide chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers
Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers Valerio Leoni, 2, *, Thomas Masterman, 2, Pria Patel, Steve Meaney, Ulf Diczfalusy,
More informationLong-term follow-up studies suggest that elevated blood
Decline in Blood Pressure Over Time and Risk of Dementia A Longitudinal Study From the Kungsholmen Project Chengxuan Qiu, MD, PhD; Eva von Strauss, PhD; Bengt Winblad, MD, PhD; Laura Fratiglioni, MD, PhD
More information김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과
치매예방을위한만성질환관리전략 김광일 서울대학교의과대학내과학교실 분당서울대학교병원내과 A sharp rise in the death rate from Alzheimer s disease Ivan Casserly & Eric Topol, Lancet 2004 Potential for primary prevention of Alzheimer s disease Alzheimer
More informationBoth total and phosphorylated tau are increased in Alzheimer s disease
624 J Neurol Neurosurg Psychiatry 2001;70:624 630 Institute of Clinical Neuroscience, Göteborg University, Sahlgrenska University Hospital / Mölndal, Sweden M Sjögren P Davidsson M Tullberg A Wallin C
More informationSetting The setting was primary care. The economic study was carried out in the United Kingdom.
The cost-effectiveness of lipid lowering in patients with ischaemic heart disease: an intervention and evaluation in primary care Hippisley-Cox J, Pringle M Record Status This is a critical abstract of
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Effect of splitting simvastatin tablets for control of low-density lipoprotein cholesterol Parra D, Beckey N P, Raval H S, Schnacky K R, Calabrese V, Coakley R W, Goodhope R C Record Status This is a critical
More informationInternational Journal of Research and Development in Pharmacy and Life Sciences. Research Article
International Journal of Research and Development in Pharmacy and Life Sciences Available online at http//www.ijrdpl.com February - March, 214, Vol. 3, No.2, pp 943-948 ISSN: 2278-238 Research Article
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationThe Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults
The Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults. Introduction Glucose intolerance is common in older individuals and this metabolic
More informationManaged Care Trends in Statin Usage GARY R. BAZALO, MS, MBA
PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.
More informationDo Statins Reduce Risk of Incident Dementia and Alzheimer Disease?
ORIGINAL ARTICLE Do Statins Reduce Risk of Incident Dementia and Alzheimer Disease? The Cache County Study Peter P. Zandi, PhD; D. Larry Sparks, PhD; Ara S. Khachaturian, PhD; JoAnn Tschanz, PhD; Maria
More informationClinical Study Cerebrospinal Fluid Levels of sappα and sappβ in Lewy Body and Alzheimer s Disease: Clinical and Neurochemical Correlates
SAGE-Hindawi Access to Research International Alzheimer s Disease Volume 2011, Article ID 495025, 6 pages doi:10.4061/2011/495025 Clinical Study Cerebrospinal Fluid Levels of sappα and sappβ in Lewy Body
More informationReview Article Total Cholesterol and the Risk of Parkinson s Disease: A Review for Some New Findings
SAGE-Hindawi Access to Research Parkinson s Disease Volume 2010, Article ID 836962, 6 pages doi:10.4061/2010/836962 Review Article Total Cholesterol and the Risk of Parkinson s Disease: A Review for Some
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationPeriodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
Drugs R D (2014) 14:221 225 DOI 10.1007/s40268-014-0061-9 ORIGINAL RESEARCH ARTICLE Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice Theodore Christou Hesham R. Omar
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationSubstantial evidence has accumulated in support of the hypothesis that elevated cholesterol
NEUROLOGICAL REVIEW Cholesterol Level and Statin Use in Alzheimer Disease II. Review of Human Trials and Recommendations Nina E. Shepardson, MS; Ganesh M. Shankar, MD, PhD; Dennis J. Selkoe, MD Substantial
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationIs There a Link between Saturated Fat Intake and Alzheimer s disease? Abstract Introduction
Is There a Link between Saturated Fat Intake and Alzheimer s disease? Justin Konig Justin will graduate in June 2015 with an Honors Biology B.S. degree. Abstract Alzheimer s disease is a neurodegenerative
More informationA cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels Maclaine G D, Patel H
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels Maclaine G D, Patel H Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More informationThe role of the vascular system in dementia
The role of the vascular system in dementia James AR Nicoll Professor of Neuropathology, University of Southampton Consultant Neuropathologist, Southampton General Hospital What does the vascular system
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationSTATINS ARE DANGEROUS DRUGS. Statins actually increase the risk of heart attacks and strokes. (!!!)
STATINS ARE DANGEROUS DRUGS Statins actually increase the risk of heart attacks and strokes. (!!!) Statins cause Type 2 Diabetes. Statins cause memory loss and cognitive decline. Statins destroy muscle
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationApart from age, environmental factors have only slight
Simvastatin strongly reduces levels of Alzheimer s disease -amyloid peptides A 42 and A 40 in vitro and in vivo K. Fassbender*, M. Simons, C. Bergmann, M. Stroick*, D. Lütjohann, P. Keller, H. Runz,S.Kühl,
More informationEffect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial
European Heart Journal (2003) 24, 1843 1847 ARTICLE IN PRESS Clinical research Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More information